IMMUTEP
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology. Their products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer. The Company's technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response.
IMMUTEP
Industry:
Biotechnology Clinical Trials Health Care Pharmaceutical
Founded:
1987-05-21
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.immutep.com
Total Employee:
11+
Status:
Active
Contact:
+33169289992
Total Funding:
19.05 M AUD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache Euro
Similar Organizations
Atlantic Healthcare
A rare disease pharmaceutical company acquiring, developing and commercializing therapeutics, specializing in gastroenterology.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
CF PharmTech
CF PharmTech is a specialty pharmaceutical company that develops and manufactures inhalation products.
Complix
Complix is a biopharmaceutical company developing Alphabodies, a novel class of biopharmaceuticals.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Gmax Biopharm
Gmax Biopharm dvelope innovative GPCR Antibody therapeutics for unmet medical use.
HealthMatch
HealthMatch connects patients with revolutionary drugs and cures.
IceCure Medical Ltd.
IceCure is a medical device company setting new standards in minimally-invasive tumor therapy women’s health and interventional oncology.
Innocare
InnoCare is a Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases.
Oncopeptides
Oncopeptides AB is a privately held clinical stage company developing melflufen, a peptidase potentiated therapy for multiple myeloma.
OneOme
OneOme is a collaborative concern between the business builder .
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
Promontory Therapeutics
Promontory Therapeutics is a clinical-stage pharmaceutical company focused on novel therapeutics in oncology.
Vaccinex
Vaccinex is a biotechnology company engaged in the development of novel therapeutic antibodies for neurodegenerative disorders and oncology.
Vesselon
Vesselon is a medical device company developing novel therapeutic Immuno-Oncology complexes.
Prescient Therapeutics
Prescient Therapeutics is a biopharmaceutical company, discovers and develops novel immunotherapeutic products for the treatment of chronic.
Current Employees Featured
Founder
Stock Details
Investors List
Australian Ethical Investment
Australian Ethical Investment investment in Post-IPO Equity - Immutep
Altium Capital
Altium Capital investment in Post-IPO Equity - Immutep
Platinum AM
Platinum AM investment in Post-IPO Equity - Immutep
Official Site Inspections
http://www.immutep.com Semrush global rank: 4.05 M Semrush visits lastest month: 3.02 K
- Host name: dd32834.kasserver.com
- IP address: 85.13.133.184
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Immutep"
Company Overview - Immutep
Corporate Presentation - immutep.com
For EO [s hina rights, Immutep may receive undisclosed milestones plus royalties; LAG525 - linicalTrials.gov (for Novartis global rights, Immutep may receive milestones plus royalties); …See details»
Immutep SA - Crunchbase Company Profile & Funding
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology. Their products include a T cell immunostimulatory factor (APC activator) for cancer chemo …See details»
Immutep - Wikipedia
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. See details»
Immutep Limited - LinkedIn
Immutep is a late-stage clinical biotechnology company developing novel LAG-3 immunotherapies to fight cancer and autoimmune disease. We are pioneers in the understanding and …See details»
Immutep - Crunchbase Company Profile & Funding
Immutep is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Immutep is dedicated to leveraging its technology and …See details»
Immutep Company Profile - Office Locations, Competitors ... - Craft
Aug 12, 2024 Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment. It develops therapeutics that …See details»
Immutep Limited (IMMP) Company Profile & Overview - Stock …
Nov 15, 2024 Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its …See details»
Immutep successfully completes institutional placement and ...
Jun 5, 2024 Immutep expects ASX to lift its trading halt and for Immutep’s ordinary shares to recommence trading on ASX on an ex-entitlements basis from market open today. Story …See details»
Annual Report - Immutep
Immutep Limited Chairman’s Letter Dear Fellow Shareholders, On behalf of the Board of Directors of Immutep Limited, it gives me great pleasure to present our Annual Report for the 2023 …See details»
IMM.AX - | Stock Price & Latest News | Reuters
Nov 23, 2024 Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for …See details»
Immutep Receives Regulatory Clearance for Phase I Study of First …
Jul 17, 2024 “The regulatory and ethical clearance for the first-in-human trial of IMP761 is a significant milestone for Immutep and marks an important step in the development of this …See details»
Immutep raises $100m and signs with Merck on ‘blockbuster’ drug
Jun 3, 2024 Immutep will have enough cash to continue until the end of 2026, he added. The company’s shares last traded at 45¢, and have risen some 10¢, or 28 per cent, since the start …See details»
Immutep Ltd Targets Lung Cancer with Promising Drug Trial
4 days ago Immutep Ltd is making strides in the battle against non-small cell lung cancer (NSCLC) by advancing its clinical candidate, eftilagimod alpha (efti), into a Phase III trial. This …See details»
Immutep: Nipping At The Heels Of LAG3.Is It Impressive Enough?
Sep 1, 2023 Immutep gave an oral presentation of TACTI-002 Phase II on SITC 2022. FDA gave fast track designation to the >1% TPS in 1L NSCLC. The reason is that, for TPS between 1 …See details»
Immutep Investor Update
Immutep was also pleased to present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 on 10-14th November 2021. In particular, we presented final …See details»
Immutep: Navigating The Bumps In The Road (NASDAQ:IMMP)
Oct 7, 2024 Summary. Immutep Limited (IMMP) has shown underwhelming results in their TACTI-003 trial, raising questions about the efficacy of their lead drug, eftilagimod.See details»
Financial Reports - Immutep
Dec 31, 2019 Annual Report 2024 Interactive version; Annual Report 2024; Appendix 4E & 2024 Full Year Statutory Accounts; Half-Year-Report - ended 31 December 2023See details»
Immutep: Realizing The Expected Catalysts, With More To Come
Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint, for various tumor types. Find out why IMMP stock is a Buy.See details»